BoneVue
Curvebeam AI / Curvebeam, LLC · Decision date Sep 11, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for BoneVue, submitted by Curvebeam AI / Curvebeam, LLC of Hatfield, Pennsylvania, on 11 September 2026 under 510(k) number K254072. The application was received on 18 December 2025. The device falls under 21 CFR 892.1170, classification name Densitometer, Bone, product code KGI, in the Radiology specialty and review panel. A SESE decision is a 510(k) clearance, not a premarket approval.
The available record describes BoneVue as post-processing software whose report addresses bone mineral density of the proximal femur and is used by physicians as an aid in determining fracture risk. The reviewed summary is a traditional 510(k), not reviewed by a third party, not a combination product, and without an authorized predetermined change control plan. The record does not identify the predicate device, the specific software changes or components assessed, or the performance data supporting equivalence; those details remain in the underlying FDA documents.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Radiology
- Decision date
- Sep 11, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K254072
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Curvebeam AI / Curvebeam, LLC
- Product code
- KGI
- Decision code
- SESE
- Decision date
- Sep 11, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Densitometer, Bone.
- Applicant
- Curvebeam AI / Curvebeam, LLC
- Product code
- KGI
- FDA device class
- 2
FDA decision timeline
K254072 received
Application receipt date recorded by FDA.
K254072 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Curvebeam AI / Curvebeam, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Hatfield, PA
Sources and methodology
- Original FDA record: K254072
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records